ArticlePCN reports : psychiatry and clinical neurosciences2025
Atypical onset of obsessive-compulsive disorder at age 50 following post-SARS-COV-2 syndrome: A case report.
Article in PCN reports : psychiatry and clinical neurosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reclaiming obsessionality: Beyond the obsessive-compulsive spectrum.PCN reports : psychiatry and clinical neurosciences · 2026Review
- Atypical onset of obsessive-compulsive disorder at age 50 following post-SARS-COV-2 syndrome: A case report.PCN reports : psychiatry and clinical neurosciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The coronavirus disease 2019 (SARS-COV-2) pandemic has been associated with an increased risk of developing or exacerbating obsessive-compulsive disorder (OCD). This report presents a case of OCD onset in a 50-year-old male following recovery from acute SARS-COV-2 infection, highlighting the potential neuroinflammatory and neuroimmune mechanisms involved. Case Presentation: Mr. A, a 50-year-old cook with no prior psychiatric history, developed a loss of smell and taste by SARS-COV-2. This sensory impairment triggered severe anxiety, leading to compulsive checking behaviors and reassurance-seeking after recovering from SARS-COV-2. Initial treatment with fluvoxamine at 50 mg/day was insufficient, and his symptoms necessitated inpatient care. His compulsive behaviors continued during hospitalization, and escalation of fluvoxamine to 150 mg/day, alongside adjunctive risperidone at 3 mg/day was needed. Along with cognitive-behavioral therapy (CBT) advises, this resulted in symptom stabilization and eventual discharge. Postdischarge, Mr. A's OCD symptoms remained stable with ongoing medication, despite continued sensory disturbances. Conclusion: This case illustrates the atypical onset of OCD in an older adult following SARS-COV-2 infection, potentially driven by neuroinflammation and altered neural pathways. The partial response to fluvoxamine and the need for risperidone suggest that SARS-COV-2-related OCD may involve complex neuroimmune changes beyond serotonin dysregulation. This case emphasizes the importance of recognizing neuropsychiatric complications in SARS-COV-2 survivors and underscores the need for further research into the mechanisms and management of SARS-COV-2-related neuropsychiatric symptoms, including OCD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.